Abstract
Background: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for p......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
